Medizinische Universität Graz - Research portal
Selected Publication:
Maier, A; Tomaselli, F; Matzi, V; Rehak, P; Pinter, H; Smolle-Jüttner, FM.
Does new photosensitizer improve photodynamic therapy in advanced esophageal carcinoma?
Lasers Surg Med. 2001; 29(4):323-327
Doi: 10.1002/lsm.1124
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Maier Alfred
- Co-authors Med Uni Graz
- Matzi Veronika
- Pinter Hans
- Rehak Peter
- Smolle-Juettner Freyja-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background and Objective: Polyhematoporphyrin (Photosan (R)) as sensitizers for photodynamic therapy (PDT) in advanced esophageal cancer carry the risk of prolonged photosensitivity of the skin. New sensitizers such as 5-aminolaevulinic acid (ALA) with low rates of skin phototoxicity appear to be promising alternatives. The aim of this study was to evaluate the efficacy of ALA compared to Photosan (R) for PDT in advanced esophageal carcinoma regarding phototoxicity of the skin, reduction of dysphagia, tumor stenosis, and tumor length and Karnovsky performance status.Study Design/Patients and Methods: After diagnostic work-up, photosensitization was done in 22 patients with ALA (60 mg/kg body weight, oral, 6-8 hours prior to PDT) and in 27 patients with Photosan (R) (2 mg/kg body weight, i.v., 48 hours before PDT). The light dose was calculated as 300 J/cm fibre tip. Light at 630 nm was applied using a pumped dye laser. In both groups, additional hyperbaric oxygenation was applied at a level of 2 absolute atmospheric pressure.Results: Improvement regarding dysphagia, stenosis diameter, and tumor length could be obtained in both treatment arms with a significant difference in favour of the Photosan (R) -group, P 0.02; P=0.0000; and P=0.000014, respectively. The Karnovsky performance status also improved in both groups and showed no significant difference (P = 0.12). The median survival time for the ALA-group was 8.0 months, compared with 9.0 months for the Photosan (R) group. No sunburn or other major treatment related complication occurred in both treatment arms. Thirty-day mortality was 0%.Conclusion: Despite the limitations of a non-randomized study, photosensitzation with Photosan (R) seems to be more effective in PDT of advanced esophageal carcinoma compared to ALA. (C) 2001 Wiley-Liss, Inc.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology
- Aged -
- Aged, 80 and over -
- Aminolevulinic Acid - adverse effects Aminolevulinic Acid - therapeutic use
- Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology
- Deglutition Disorders - drug therapy Deglutition Disorders - pathology
- Dermatitis, Phototoxic - etiology
- Esophageal Neoplasms - drug therapy Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology
- Female -
- Hematoporphyrins - adverse effects Hematoporphyrins - therapeutic use
- Humans -
- Karnofsky Performance Status -
- Male -
- Middle Aged -
- Photochemotherapy - adverse effects
- Photosensitizing Agents - adverse effects Photosensitizing Agents - therapeutic use
- Pilot Projects -
- Survival Rate -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- esophageal cancer
- photodynamic therapy